Bottom line: cancer before or after orthotopic heart transplant (OHT) requires a joint transplant–oncology plan. Do not use “history of cancer,” a positive EBV PCR, or a new solid tumor as an automatic instruction to deny OHT, hold the antimetabolite, withdraw CNI, or convert to mTOR. Define the cancer phenotype, intent and prognosis; then protect enough antitumor immunity and enough graft immunity. Adult-focused; pediatric care requires a separate pathway.
A
Why the burden looks different across studies
definitions · competing risk · survivor denominator
| Source | Observed burden | How to use it |
|---|
| ISHLT registry summary | All malignancies in 16% of 5-year survivors and 28% of 10-year survivors; skin cancer was most common, followed by prostate and lung cancer. | Survivor prevalence; it is not cumulative incidence from transplant. |
| SRTR · 51,597 adults | Reported de novo cancer estimates 3%, 16.4%, 32.8%, 56.6% at 1, 5, 10 and 20 years; diagnosis associated with higher mortality (adjusted HR 2.14). | Useful for prognosis; non–competing-risk estimates should not replace the contemporary teaching estimate. |
| UNOS · 50,370 recipients | Ten-year incidence 20.6%: nonmelanoma skin 9.0%, solid-organ 6.2%, lymphoproliferative 1.2%. | Different methods yield a lower 10-year estimate; do not average the studies into a false “true” number. |
Teaching number: approximately one in five by 10 years. Quote the study and method when precision matters; do not combine discordant registry estimates into one “true” incidence.
B
Three interacting risk engines
risk is dynamic
Recipient / cancer biologyAge · prior cancer/field therapy · inherited predisposition · tobacco/UV/HPV exposure · organ function · recurrence kinetics · residual disease · frailty.
Transplant / immune pressureTime since OHT · cumulative and recent lymphocyte depletion · rejection treatment · intensity and duration of maintenance therapy · EBV D/R status · infection burden.
Current treatmentCurative vs palliative intent · marrow, renal and cardiac toxicity · CYP3A/P-gp interactions · wound healing · need for ICI · expected time to benefit.
C
Choose the correct clinical lane first
different lane · different action
| Lane | First question | Default owner / next move |
|---|
| Cancer before OHT | Will cancer-specific survival or recurrence under immunosuppression materially compromise expected post-OHT benefit? | Selection committee + disease oncologist; stage/biology-based review, not an elapsed-time rule. |
| Prevention / screening | Which standard screens and transplant-amplified risks are due now? | Transplant clinic + primary care + dermatology/gynecology; close the referral loop. |
| New lesion / solid tumor | Is there tissue, stage, treatment intent, urgency, and a complete interaction map? | Oncology + transplant attending + pharmacist before changing immunosuppression. |
| PTLD / EBV syndrome | Is this tissue-defined PTLD, EBV DNAemia without disease, infection, or another lymphoma? | Transplant center + hematopathology/hematology + transplant ID; PTLD-specific reduction/treatment pathway. |
| Cancer therapy in OHT | Can effective non-ICI therapy be used, and what threatens graft, kidney, marrow, or drug exposure? | Cardio-oncology + oncology + transplant pharmacy; therapy-specific monitoring. |
D
Five statements to prevent predictable harm
fact-check
Biopsy beats assumptionEBV DNAemia, PET avidity, and a skin photograph do not replace tissue when tissue is safely obtainable.
Solid tumor ≠ PTLDRoutine global immunosuppression reduction is not evidence-based for every non-lymphoid cancer.
mTOR ≠ cancer therapyAssociations with lower future malignancy do not prove treatment of an established tumor.
ICI may cost the graftHeart allograft rejection may be fatal; kidney-dominant pooled data understate the practical consequence.
One-sentence problem representation: “OHT ___ years ago; current graft/CAV/rejection/DSA status ___; cancer ___ stage/biology, intent and alternatives ___; current immunosuppression ___; immediate interaction/toxicity issue ___; decision required by ___.”
ISHLT boundary: screen candidates according to current general-population recommendations and obtain individualized oncology risk stratification. OHT is reasonable when cancer-related survival is not expected to limit post-transplant survival and recurrence risk is low based on tumor type, response and negative metastatic evaluation. Routine occult-cancer PET screening in an otherwise asymptomatic person is not established.
A
Oncology clearance: required data
no “cleared” without inputs
| Domain | Record explicitly | Why it changes OHT risk |
|---|
| Diagnosis | Primary site; histology; grade; molecular subtype; date; whether cancer was therapy-related or associated with a cancer-predisposition syndrome | Recurrence kinetics and sensitivity to immunosuppression vary within the same organ label. |
| Stage / residual disease | Original and current stage; margin/nodal status; metastatic sites; current imaging; measurable/minimal residual disease tests only where disease-validated | “No evidence of disease” must be tied to a method and date; ctDNA is not a universal clearance assay. |
| Treatment / response | Surgery, radiation field/dose, systemic agents and cumulative anthracycline; completion date; best/current response; maintenance therapy; planned surveillance | Defines recurrence hazard, future treatment feasibility and graft/vascular/marrow toxicity. |
| Prognosis | Cancer-specific survival with and without OHT; expected time to recurrence; salvage options; competing HF mortality on current support | The relevant comparison is transplantation versus the realistic HF alternative, not cancer risk in isolation. |
| Immune dependence | Melanoma, lymphoma, HPV/virus-related tumor, sarcoma, hematologic disease, prior ICI or cellular therapy | Some diseases or treatments have special recurrence/rejection uncertainty; use disease-specific consensus. |
B
Decision lanes—not universal wait times
committee judgment
| Lane | Typical phenotype | Committee action |
|---|
| Proceed / no added delay | Definitively treated very-low/low-risk disease with favorable biology and no evidence of residual/metastatic disease; expected cancer survival does not constrain OHT benefit | Document disease-specific rationale and surveillance; some low-risk tumors require no arbitrary observation interval after standard therapy. |
| Observe / bridge | Intermediate recurrence risk, incomplete staging, recent treatment with recurrence hazard front-loaded in the next several years, or surveillance not yet interpretable | Set a dated re-review, required test and objective threshold; use durable support/medical bridge when appropriate. |
| Defer | Active progressive disease, incomplete curative therapy, metastatic/noncurative cancer whose expected survival compromises OHT benefit, or no feasible post-OHT treatment plan | Continue cancer/HF therapy and reassess if biology/response changes; define palliative goals when candidacy will not become realistic. |
| Exceptional review | Indolent hematologic disease, chronic maintenance therapy, prior ICI, molecular residual-disease discordance, rare tumor, or life-threatening HF with little time to observe | Multidisciplinary written risk estimate; external disease expert or tumor board when evidence is sparse. |
C
Pre-list checklist
close every loop
- Screening current breast, colorectal, lung, cervical/prostate and skin pathway; dental/oral and symptom-directed evaluation.
- Dermatology full-body examination; resolve active suspicious lesions before listing when feasible.
- Therapy record exact agents, cumulative doses, radiation fields, transfusions, lines, infections, neuropathy, renal/marrow reserve.
- Cardio-oncology phenotype LV/RV function, diastology, valve/pericardial disease, coronary/radiation vasculopathy and arrhythmia.
- Future options can recurrence be biopsied/staged/treated after OHT; would required ICI create an unacceptable graft tradeoff?
- ICI exposure record agent, final dose, immune toxicities and response. No validated universal “washout” makes subsequent OHT safe.
- Plan ownership name oncologist, surveillance interval, trigger for re-staging and pathway if cancer recurs on the waitlist.
- Consent explain recurrence, second-primary and treatment-limitation risks in addition to routine OHT risks.
D
What contemporary survivor data do—and do not—show
selected cohort
| Columbia 2000–2020 | Among 1,332 OHT recipients, 104 were selected cancer survivors; 22 developed a subsequent primary cancer, with 18 de novo cancers and 4 recurrences. Survival was comparable or better than the non-cancer-survivor group. |
| Correct inference | Carefully selected survivors can derive durable OHT benefit, and prevention must address new primaries rather than focusing only on recurrence. |
| Wrong inference | This single-center retrospective survivor cohort does not validate a universal wait interval, guarantee safety for active/high-risk disease, or remove selection and immortal-survivor bias. |
Committee sentence: “Cancer ___, stage/biology ___, treated ___, response/NED method and date ___; estimated recurrence and cancer-specific survival ___; immunosuppression-sensitive concern ___; proposed wait/re-review ___; post-OHT surveillance/treatment feasibility ___; oncology owner ___.”
Do at the anniversary visit: reconcile the last completed test, result, next due date, ownership and barriers. ISHLT recommends current general-population screening for breast, colon, prostate, lung and other solid tumors, plus preventive education and yearly dermatologic examination for adult OHT recipients.
A
High-yield screening matrix
as of 2026-08-25
| Site | Minimum practical pathway | Transplant modification / caveat |
|---|
| Skin | Full-body dermatology examination at least yearly; shorter interval after skin cancer or by risk. New concerning growth: expedited dermatology, generally within 1–2 weeks. | Thoracic transplant is high risk. Record burden, field cancerization, nodal symptoms and dermatology interval; do not delay biopsy for an immunosuppression decision. |
| Breast | Average-risk persons assigned female at birth age 40–74: biennial mammography under current USPSTF guidance. | Prior chest radiation, genetic syndrome, breast cancer/high-risk lesion or symptoms follow a higher-risk pathway—not this interval. |
| Colorectal | Average risk: screen 45–75; age 76–85 selective by health, prior screening and preference. Use an accepted stool, endoscopic or imaging strategy with completion of diagnostic colonoscopy after an abnormal noninvasive test. | Prior polyps/cancer, IBD or hereditary syndrome requires disease-specific surveillance. |
| Lung | Annual LDCT age 50–80 with ≥20 pack-years and current smoking or quit within 15 years; stop when curative treatment is not feasible. | Tobacco cessation is treatment. Do not substitute routine chest radiographs or symptom-only screening. |
| Cervix | SOT recipients should follow an immunocompromised/HIV-pattern cervical screening pathway, not average-risk intervals; engage gynecology for age/history-specific testing and abnormal-result follow-up. | HPV vaccination does not remove the need for intensified surveillance. |
| Anal / HPV related | IANS recommends beginning anal cancer screening 10 years after SOT when diagnostic high-resolution anoscopy capacity exists; start earlier by other high-risk criteria/history. | Screening is a program, not an isolated cytology test—abnormal results need HRA access and treatment capacity. |
| Prostate / oral / other | Use current shared-decision and risk-based general guidance; inspect oral cavity and act on hematuria, bleeding, mass, unexplained anemia/weight loss or persistent focal symptoms. | No evidence supports universal whole-body PET/CT, broad tumor-marker panels or liquid-biopsy screening in asymptomatic OHT recipients. |
B
Skin-cancer prevention that survives fact-checking
dermatology-led
- Do daily broad-spectrum sun protection, protective clothing/hat, avoid tanning devices, regular self-examination and rapid review of a changing/nonhealing lesion.
- Field disease dermatologist-directed lesion/field therapy; high-rate or high-risk cSCC may justify acitretin and a transplant-team discussion of immunosuppression modification.
- After cSCC record tumor risk features, nodal surveillance plan and cadence; prevention intensity follows burden and biology, not just “history: yes/no.”
- Nicotinamide do not promise benefit by extrapolating from immunocompetent adults: the transplant RCT found no reduction in keratinocyte cancers or actinic keratoses and ended early for poor recruitment.
- mTOR a possible secondary-prevention component, not a substitute for excision, staging or dermatology; tolerance and rejection risk govern conversion.
- Equity examine all skin types. Do not encode race as a stand-alone biologic rule or assume low risk when UV damage is less visible.
C
Vaccines and infection-linked cancer prevention
before OHT when feasible
| Action | Operational point |
|---|
| HPV vaccine | Complete vaccination through age 26 if not adequately vaccinated; age 27–45 by shared decision. Immunocompromised persons use a 3-dose series; vaccination prevents new infection and does not treat existing HPV disease. |
| HBV / HCV | Vaccinate for HBV when indicated and treat chronic HBV/HCV through specialist pathways; before anti-CD20 or highly immunosuppressive cancer therapy, re-screen and set a reactivation plan. |
| Tobacco / alcohol | Assess at every visit; provide medication plus behavioral cessation support. Tobacco exposure drives lung and other cancers and is associated with post-OHT malignancy in registry data. |
Annual prevention line: “Derm exam/result/next due ___; breast ___; colorectal ___; lung eligibility ___; cervical/anal pathway ___; prostate/other risk ___; HPV/HBV status ___; tobacco/UV counseling ___; referrals closed ___.”
First rule: unless there is an immediate toxicity or transplant-attending instruction, continue the current immunosuppression while the diagnosis is clarified. A casual “hold MMF” can precipitate rejection, obscure the intended treatment plan and still fail to control the cancer.
A
Triage before the tumor board
same day · urgent · planned
| Tempo | Examples | Action |
|---|
| Emergency | Airway/cord/CNS compromise; hemodynamic instability; tumor lysis; major bleeding; febrile neutropenia/sepsis; new graft dysfunction or malignant arrhythmia | ED/admission; stabilize; notify transplant and oncology; preserve/re-route immunosuppression during NPO/organ failure. |
| Expedited | Rapidly enlarging mass, B symptoms/cytopenias, suspicious graft-adjacent lesion, EBV DNAemia plus symptoms, new neurologic finding, high-risk skin growth | Imaging/tissue and specialist review within days; do not wait for a routine surveillance visit. |
| Structured | Screen-detected lesion in a stable recipient | Complete diagnostic test/biopsy, stage and set treatment intent before immunosuppression redesign. |
B
Minimum diagnostic and graft bundle
before the first cancer dose
| Workstream | Required inputs | Owner |
|---|
| Pathology | Adequate tissue; histology/grade; biomarkers/molecular testing that changes therapy; EBER/CD20 and hematopathology review when PTLD/lymphoma is possible | Oncology / pathology |
| Stage / intent | Disease-specific imaging/labs; curative, disease-control or palliative intent; urgency; expected benefit and alternatives; anticipated surgery/radiation | Disease oncologist / tumor board |
| Allograft | Symptoms/exam; ECG; echo ± GLS; troponin/NP when therapy or graft concern; latest CAV study, EMB/pAMR, DSA, rejection history and current graft function | OHT / cardio-oncology |
| Host reserve | CBC/differential; CMP/eGFR, liver tests, Mg; urine protein when VEGF/mTOR relevant; infection symptoms; EBV/CMV by phenotype; HBV/HCV/HIV before B-cell therapy | Oncology / ID / transplant |
| Medication map | Actual tac/cyclosporine/mTOR doses and trough; antimetabolite/steroid; prophylaxis; QT drugs; CYP3A/P-gp inhibitors/inducers; marrow/nephrotoxic overlap; oral adherence/absorption | Transplant pharmacist |
| Execution | One treatment calendar; lab/trough timing; hold/restart rules; rejection and infection escalation; after-hours numbers; goals-of-care and caregiver plan | Named coordinating clinician |
C
Classify before changing immunosuppression
four branches
PTLD / lymphomaTissue + EBV context; reduction is part of treatment, then response-adapted hematology therapy.
Non-lymphoid solid tumorNo routine blanket reduction; adjust for toxicity, interaction, surgery or individualized antitumor rationale.
Skin cancerExcise/stage first; burden and high-risk features drive dermatology prevention and possible IS redesign.
Infection / mimicFungal, mycobacterial, viral and inflammatory lesions can mimic cancer; identify before escalating chemotherapy or reducing graft protection.
D
Could it be donor-derived?
patient-safety clock
- Suspect when unusual early timing, tumor in/adjacent to the allograft, donor malignancy discovered post-procurement, or genetically/sex-chromosome/molecularly donor-consistent disease.
- Do not wait for every molecular result before safety communication when substantial concern exists.
- U.S. reporting notify the host OPO and report through the OPTN Improving Patient Safety pathway as soon as possible and within 24 hours when required; this allows other recipients to be assessed.
- Parallel care continue diagnostic and treatment planning; reporting does not establish causality.
New-cancer handoff: “Tissue ___; stage/intent/alternatives ___; urgency ___; graft/CAV/rejection/DSA baseline ___; renal/marrow/infection reserve ___; interaction flags ___; immunosuppression decision and owner ___; surveillance ___; donor-derived concern/reporting ___.”
PTLD is not one disease: early/nondestructive, polymorphic, monomorphic B- or T/NK-cell and classic Hodgkin-type entities differ. Early disease is often EBV-positive; late disease may be EBV-negative. A negative blood EBV result does not exclude tissue PTLD.
A
When to suspect and how to diagnose
do not diagnose by PCR
| Signal | Evaluation | Pitfall |
|---|
| Systemic / nodal | Fever, night sweats, weight loss, adenopathy, organomegaly, cytopenias, LDH change, unexplained graft/organ dysfunction | Infection and drug toxicity overlap; broad differential remains mandatory. |
| Extranodal | GI pain/bleeding, pulmonary lesion, skin/oral lesion, allograft involvement, focal neurologic/cognitive change | PTLD is often extranodal; a normal node exam is not reassuring. |
| EBV DNAemia | Repeat in the same specimen/assay when possible; trend; examine and image by phenotype; review D/R status and recent lymphocyte depletion | No universal cross-laboratory threshold; DNAemia alone is neither PTLD nor an automatic rituximab indication. |
| Definitive test | Excisional/core tissue when safely possible for architecture, WHO/ICC classification, EBER, CD20 and disease-specific studies | Fine-needle aspirate may be inadequate; empiric treatment can erase diagnostic tissue. |
B
Stage and prepare before therapy
transplant center
- Disease PET/CT when appropriate; CBC/CMP, LDH, uric acid; marrow, CNS, GI or organ-specific evaluation by histology/symptoms.
- Virology quantitative EBV and CMV; HBsAg, total anti-HBc, anti-HBs; HCV/HIV; plan HBV prophylaxis before anti-CD20 when indicated.
- Urgency bulky, rapidly progressive, organ-threatening, CNS or unstable disease should not wait through a prolonged reduction-only trial.
- Graft echo/graft function; ECG; DSA and recent ACR/pAMR; CNI/mTOR trough; CAV/renal reserve.
- Infection prophylaxis and growth-factor plan; immunoglobulin only when clinically indicated—not as PTLD treatment.
- Fertility / access preserve time-sensitive options; verify infusion access, caregiver, payer and urgent contact pathway.
C
Adult CD20-positive pathway: evidence map, not an order set
hematology-owned
| Step | Evidence-supported concept | OHT guardrail |
|---|
| 1 · Reduce net IS | Reduction in immunosuppression (RIS) is the best-validated first intervention. Common frameworks stop/reduce AZA/MMF and lower CNI, but no universal OHT dose or taper exists. | Transplant attending writes the exact regimen and graft-surveillance plan; do not stop every agent. |
| 2 · Rituximab induction | For appropriate CD20-positive adult PTLD not adequately controlled by RIS: rituximab 375 mg/m² weekly ×4, then restage in the PTLD-1 response-adapted strategy. | Trial regimen is an evidence descriptor; hematology/pharmacy verify dosing, HBV plan, infection risk and infusion precautions. |
| 3 · Response-adapt | Complete response received rituximab consolidation; lesser response/progression received R-CHOP-21 in the prospective trial. Overall response 88%, complete response 70%; grade 3–4 infection 34% and treatment-related mortality 8%. | Use current disease-specific pathway; frailty, cardiac/renal reserve, histology and tempo may require a different regimen. |
| 4 · Exceptions | CD20-negative, T/NK-cell, classic Hodgkin-type, Burkitt, plasmablastic, primary CNS, localized or relapsed/refractory disease require histology/site-specific therapy. | Specialized center/clinical trial; consider surgery, radiation or cellular therapy only by disease context and availability. |
D
Graft and infection safeguards during PTLD care
every RIS step has a countermeasure
| Allograft | Clinical/ECG/echo assessment; DSA and EMB ± RHC when symptoms, dysfunction, biomarker/immune signal or major reduction warrants. Molecular tests do not replace biopsy when concern exists. |
| Infection | PJP and antiviral strategy by regimen; neutropenia plan; HBV prophylaxis/monitoring with anti-CD20; CMV/EBV trends by phenotype; vaccinations before therapy when feasible. |
| What not to do | Do not use antiviral therapy or IVIG alone as PTLD prevention/treatment; do not equate falling EBV DNA with complete tissue response; do not continue a failing RIS-only trial in aggressive disease. |
PTLD plan sentence: “Pathology/classification/CD20/EBER ___; stage/sites/tempo ___; RIS exact changes ___; graft/DSA/EMB plan ___; rituximab/chemotherapy pathway ___; HBV/PJP/growth-factor plan ___; response assessment date ___.”
Critical correction: ISHLT finds no evidence supporting routine immunosuppression reduction solely because a recipient has a non-lymphoid solid tumor; continue maintenance unless there is a specific reason to change an agent. PTLD, severe infection/toxicity, marrow suppression, a major interaction or an individualized cancer-prevention strategy are distinct indications.
A
Start with the reason—not the drug
one axis at a time
| Trigger | Possible redesign | Guardrail |
|---|
| PTLD | Staged RIS as part of disease treatment; commonly reduce/stop antimetabolite and lower CNI, then response-adapted therapy | Exact regimen and graft surveillance owned by OHT; no automatic complete withdrawal. |
| Chemotherapy cytopenia / infection | Temporarily reduce marrow-suppressive antimetabolite or other culprit; rationalize valganciclovir/TMP-SMX and treatment overlap | Use ANC/platelets/diagnosis and duration; specify replacement/restart criteria rather than “hold until better.” |
| CYP3A/P-gp interaction | Change anticancer/supportive drug when possible or pharmacist-directed CNI/mTOR adjustment with frequent troughs | Starting and stopping an inhibitor/inducer changes exposure; avoid fixed generic percentage reductions. |
| Kidney / neuro / TMA toxicity | CNI minimization; reduced-CNI + mTOR when eligible; exceptional CNI-free rescue or belatacept pathway | Re-phenotype toxicity and maintain graft coverage; cancer is not evidence that CNI caused the organ injury. |
| Multiple/high-risk cSCC | Dermatology prevention plus discussion of overall burden, AZA substitution and/or reduced-CNI/mTOR strategy | Prioritize excision/staging; use tumor burden, rejection history, CAV, renal function, proteinuria and mTOR tolerance. |
| Major surgery / wound | Prewritten mTOR hold/bridge and restart after adequate healing; maintain other immunosuppression by oral/IV route | Do not delay urgent cancer surgery. Coordinate any mTOR interruption, replacement and restart with the transplant and surgical teams. |
B
Agent-by-agent cancer interface
toxicity · interaction · rejection
| Agent | Potential reason to change | Do not assume |
|---|
| MMF / AZA | Neutropenia, thrombocytopenia, infection, GI injury or overlapping cancer-therapy marrow toxicity; AZA has an established skin-cancer concern in transplant practice | Every solid tumor requires holding MMF; every WBC fall is caused by MMF; reduction is harmless. |
| Tac / cyclosporine | CYP3A/P-gp interactions, AKI, neurotoxicity, TMA, diabetes/HTN; reduce only with trough and graft plan | CNI withdrawal improves cancer control or is safe because the echo is normal. |
| Sirolimus / everolimus | May permit lower CNI and may be considered in selected recurrent skin cancer, malignancy-risk, CAV or renal phenotypes | It treats the active cancer, prevents all recurrence, has a universal “cancer” trough, or can be started through unhealed surgery/proteinuria/pneumonitis. |
| Corticosteroid | Individualize for rejection history and chemotherapy regimen; minimize chronic exposure when safe | Reflex withdrawal during another major regimen change is safe; steroid used in chemotherapy automatically supplies all graft coverage. |
| Belatacept | Separate off-label CNI-toxicity rescue pathway in rigorously selected EBV-seropositive recipients; see OHT belatacept guide | Do not use it as a cancer-sparing strategy; it carries PTLD/CNS, serious-infection and malignancy warnings and is not established for routine OHT. |
C
What the heart-specific sirolimus signal means
association, not proof
- Cohort single center, 523 OHT recipients, median 10-year follow-up; 307 converted to sirolimus-based and 216 remained CNI-based.
- Associations lower composite de novo malignancy excluding NMSC (adjusted HR 0.34; this composite included PTLD), PTLD (0.13) and subsequent NMSC (0.44). First NMSC was not reduced.
- Limits retrospective, nonrandomized conversion; selection, tolerance, era, treatment-indication and time-dependent biases remain.
- Valid use supports a multidisciplinary discussion of prevention-oriented conversion—not a claim that sirolimus treats an existing tumor or improves cancer-specific survival.
D
Write an executable redesign
before first change
Define intentPTLD treatment · cytopenia · interaction · renal/CAV benefit · secondary skin prevention.
Measure graft riskTime post-OHT · prior ACR/AMR · DSA/cPRA · graft function · CAV · adherence/exposure.
Name exact regimenDrug/dose/target/step dates; do not use “minimize IS” or “mTOR ± MMF.”
Build countermeasuresTrough/CBC/CMP/protein/lipid · DSA/echo/EMB · infection prophylaxis · hold/restart/bridge.
Regimen safety: a malignancy diagnosis does not specify an immunosuppression regimen. Name the indication, retained agents, target exposure, graft surveillance, wound and proteinuria constraints, and restart criteria.
IS plan sentence: “Change is for ___ (not cancer label alone); from ___ to ___ on dates ___; target troughs ___; marrow/renal/wound/infection checks ___; echo/DSA/EMB plan ___; bridge and restart/stop criteria ___; owner ___.”
ICI warning: in a 2025 individual-patient meta-analysis of 343 SOT recipients, acute rejection occurred in 36.2% and graft loss in 18.4% by 1 year; objective response was 31.6%. The cohort was 70.9% kidney recipients and included few heart recipients, so the exact OHT rate is uncertain—but heart graft loss has no dialysis-like rescue.
A
Immune checkpoint inhibitor decision gate
not a routine contraindication checklist
| Before ICI | Document | Hard truth |
|---|
| Oncologic value | Intent, biomarker, expected response/survival, time to benefit and all effective non-ICI alternatives | Use only when expected benefit plausibly justifies severe/fatal rejection risk; patient values are central. |
| Graft risk | Time since OHT; prior ACR/AMR; DSA; graft function; CAV; current IS; adherence; feasibility of MCS/rescue and retransplant limitations | No ICI agent, IS regimen, prophylactic strategy or surveillance schedule is proven safe in OHT. |
| Baseline | ECG; echo/LVEF/GLS; troponin and NP; DSA; recent EMB/clinical rejection assessment; CBC/CMP/Mg; thyroid and therapy-specific labs | These are a conservative center-build scaffold, not validated rejection prevention. |
| Immunosuppression | Transplant-written regimen before cycle 1; avoid simultaneous unowned changes; verify every dose actually taken | Do not preemptively stop CNI/mTOR to improve ICI efficacy. Retrospective mTOR/steroid associations are hypothesis-generating. |
| Early monitoring | Symptoms, ECG, troponin/NP and graft imaging at a center-defined high-intensity cadence; low threshold for DSA/EMB ± RHC | ICI myocarditis and allograft cellular/antibody-mediated rejection can overlap; biomarkers cannot reliably distinguish them. |
B
Hold and escalate for a graft signal
hours, not next cycle
ClinicalDyspnea · edema · fatigue · syncope · palpitations · fever · hypotension.
ElectricalNew arrhythmia · heart block · ST/T change · QT issue.
Biochemical / imagingTroponin/NP rise · new dysfunction/strain change · DSA signal.
ActionHold ICI; urgent OHT/cardio-oncology review; echo + DSA + EMB/RHC as indicated; treat defined syndrome.
Rechallenge: exceptional, after multidisciplinary review of cancer response/alternatives, rejection severity and recovery, residual graft risk, immunosuppression plan and informed patient preference.
C
Non-ICI therapy: high-yield graft interfaces
standard oncologic indication · adapted execution
| Therapy | OHT-specific concern | Control |
|---|
| Anthracycline / HER2 | Prior exposure, graft diastolic reserve, CAV/radiation disease and renal function matter; denervation does not protect myocardium | Cardio-oncology risk stratification and therapy-specific echo/GLS + biomarkers; see Cardio-Oncology. |
| VEGF / many TKIs | HTN, HF, ischemia/thrombosis, QT, proteinuria and CYP3A/P-gp effects; mTOR/CNI toxicity can compound | BP, ECG/QT, renal/protein and trough plan; choose noninteracting alternative when efficacy is comparable. |
| Fluoropyrimidine | Vasospasm/ischemia; denervation can blunt angina and CAV may lower coronary reserve | Urgent evaluation of symptoms/electrical/biomarker change; oncology/cardiology rechallenge plan if ever considered. |
| Platinum / ifosfamide | AKI, Mg wasting, dehydration and tumor lysis compound CNI nephrotoxicity | Hydration/electrolyte plan, renal dosing, frequent CNI/mTOR trough and avoidance of additional nephrotoxins. |
| Marrow-suppressive therapy | Additive MMF/AZA, valganciclovir and TMP-SMX cytopenia; infection may prompt harmful ad hoc IS holds | ANC/platelet-based plan, growth factor/prophylaxis as indicated, and exact antimetabolite restart criteria. |
| Anti-CD20 / B-cell therapy | HBV reactivation, hypogammaglobulinemia, infection and vaccine-response loss | HBsAg/anti-HBc/anti-HBs before therapy; high-barrier antiviral prophylaxis/monitoring when indicated. |
D
Interaction, surgery and radiation rules
pharmacist before dose 1
- CYP3A/P-gp tacrolimus, cyclosporine, sirolimus and everolimus are narrow-index substrates. Many TKIs, azoles/macrolides and antiemetics raise levels; strong inducers such as some androgen-receptor agents or anticonvulsants can markedly lower them.
- Timing check trough/organ labs after start, stop and dose change; diarrhea, vomiting and NPO status alter exposure.
- No fixed rule use an interaction-specific plan; a generic 50% tac reduction is unsafe.
- Surgery do not routinely stop all immunosuppression; create an oral/IV route plan. mTOR may require pre-op substitution and restart only after adequate healing.
- Radiation RT alone is not an indication to lower IS. Thoracic fields require contemporary heart/coronary/graft and lung constraints; no separate validated transplanted-heart constraint set exists.
- Prophylaxis base PJP/viral/antibacterial/antifungal strategy on combined transplant + chemotherapy + steroid + neutropenia risk and interaction burden.
At each transition: answer four questions—Is the cancer responding? Is the graft stable? Is toxicity/infection acceptable? Does the plan still match the patient’s goals? A normal LVEF, negative EBV PCR or completed chemotherapy answers only one small part.
A
Monitoring clock by phase
individualize to therapy and graft risk
| Phase | Cancer / treatment | Allograft / transplant | Decision |
|---|
| Before treatment | Pathology, stage, intent, alternatives, response metric/date; CBC/CMP/organ and infection baseline; fertility/goals | ECG, graft function/echo ± GLS, CAV context, prior ACR/pAMR, DSA, current IS/trough, interaction map | Approve regimen, IS plan, surveillance, prophylaxis, emergency pathway and owners. |
| Early cycles / peri-op | Response/toxicity; fever/neutropenia; wound; renal/marrow/ECG/therapy-specific labs | Actual IS doses/trough; symptoms, ECG/echo/biomarkers by risk; DSA/EMB when ICI, major IS reduction or graft signal | Change one axis at a time; specify hold, bridge and restart. |
| Response assessment | Objective response/progression; remaining curative options; cumulative toxicity | Graft trajectory, rejection/DSA, CAV, renal function, infection and achieved IS exposure | Continue, de-intensify, redesign or stop based on both outcomes—not cancer imaging alone. |
| Survivorship | Disease-specific recurrence surveillance; late effects; rehabilitation; second-primary prevention | Return to standard OHT follow-up with therapy-tailored cardio-oncology surveillance and rational minimum effective IS | Update a written care plan and assign every screen/result. |
| Progressive disease | Expected benefit/time to benefit of next line; symptom burden; hospice/palliative options | Graft support, interactions, burden of biopsies/infusions and implications of IS changes | Align treatment intensity with goals; do not equate palliation with abrupt abandonment of anti-rejection therapy. |
B
Survivorship priorities
recurrence + second primary + late toxicity
- Cancer surveillance follow disease-specific oncology schedule; keep age/risk screens current rather than assuming recurrence imaging covers all organs.
- Second primaries selected OHT cancer survivors developed more de novo cancers than recurrences; skin/HPV/tobacco prevention stays active.
- Late effects marrow, renal, neuropathy, endocrine, vascular, coronary/radiation and cardiomyopathy surveillance by prior exposure.
- Rehabilitation nutrition, exercise, vaccination, bone/fall health, mental health, sexual health, fertility and return-to-work.
- Medication cleanup remove temporary prophylaxis only when the combined immune risk permits; reconcile every CNI/mTOR interaction after cancer drugs stop.
- Caregiver / access transportation, infusion and laboratory reliability, cost and language/access support are clinical safety variables.
C
Hard future decisions
prepare before crisis
| Decision | Minimum discussion |
|---|
| ICI despite OHT | Expected cancer benefit and alternatives; potential fatal rejection/graft loss; monitoring limitations; rescue feasibility; explicit patient preference. |
| Major IS reduction | Exact antitumor rationale; rejection probability; which agent/target changes; graft monitoring; replacement/restart; what outcome ends the trial. |
| Retransplant / MCS | Cancer status and recurrence risk, expected survival, sensitization/rejection history, prior ICI, current treatment and allocation/center eligibility; no automatic promise. |
| Advanced cancer | Time to benefit, symptom relief, graft-related burden, code status, device/ICD plan, preferred site of care and who will manage immunosuppression near end of life. |
D
Program governance and copy-ready note
local adoption gate
Clinical ownersNamed OHT, disease oncology/hematology, cardio-oncology, pharmacist, ID and specialty partners.
Operational buildShared medication list, therapy calendar, trough/lab timing, result inbox, after-hours and admission pathway.
Safety / reportingPTLD and malignancy data capture; donor-derived 24-hour pathway; interaction and missed-dose review.
Learning systemTrack cancer response/survival, rejection/DSA/graft loss, infection, renal/marrow toxicity, IS exposure and patient goals.
Copy-ready consult summary:
Cancer: ___ histology/stage/biology; intent ___; treatment/alternatives ___; response assessment ___
OHT: date ___; graft/CAV ___; prior ACR/pAMR/DSA ___; current IS/trough ___
Risks: interaction ___; marrow/renal/infection/wound/cardiotoxicity ___; ICI/donor-derived concern ___
Plan: cancer therapy ___; IS exact change or continuation ___; graft/cancer/lab surveillance ___; prophylaxis ___; hold/bridge/restart ___; owners ___; goals/reassessment date ___
Evidence boundary: this is a clinical education guide, not a prescribing protocol or order set. Screening guidance changes over time; PTLD and ICI evidence is dominated by non-heart SOT populations; heart-specific mTOR cancer evidence is observational. Verify current labels, society guidance, current transplant guidance and patient-specific oncology pathways at use.